Trulieve Cannabis (TRLV): A $406 Million Loss Or a $598 Million Unlock?

Trulieve Cannabis (TRLV) reported Q2 2026 adjusted EPS of $0.11, beating the consensus estimate of roughly $0.08. Revenue came in at $271 million, broadly in line with expectations. The stock fell 2.8% on the report. The same stock is down 26% year-to-date on the NYSE, having uplisted from OTC trading on June 10 — becoming the first U.S. cannabis operator on a major exchange.

The headline number that explains the selloff is the GAAP net loss: $406 million. It looks like a disaster. It isn't.

The entire loss is a non-cash accounting charge from the June 3 deconsolidation of Trulieve's mixed-use "Harvest" business. Trulieve separated its DEA-registered medical operations from the non-medical Harvest unit to satisfy NYSE listing requirements. The move was painful on paper. It was deliberate.

The medical core that remains is intact. Medical-only revenue climbed 4% sequentially to $222 million. Gross margin sat at 60%, with gross profit of $162 million. Adjusted net income turned positive at $20.4 million, a reversal from the $7.7 million loss a year ago. Trulieve retains a 90% economic interest in Harvest — it still owns nearly all of it. It just no longer controls it day to day.

The valuation has disconnected from the cash-generating core

The market is pricing Trulieve as a company in structural distress. The numbers argue otherwise.

Trulieve trades at 4.5 times EV/EBITDA and 1.4 times trailing sales. That is the multiple range of a cash-generative business facing existential threats. Trulieve's trailing twelve-month free cash flow stands at $224 million — a 531% year-over-year increase — against a $1.68 billion market cap. That translates to a free cash flow yield of roughly 13%. For context, most mid-cap industrials don't clear 5%.

The balance sheet reinforces the setup. Trulieve sits on $325 million in cash with $289 million in debt, putting it in net-negative-debt territory. The current ratio of 5.3x and quick ratio of 3.3x suggest the company has no near-term liquidity concern. Debt-to-equity sits at a manageable 9.2%. Management also authorized a $50 million share repurchase program — not something a company in distress typically does.

The market has arguably baked in a scenario where the Harvest deconsolidation signals an unraveling business. The underlying cash flow trajectory suggests otherwise.

The Schedule III catalyst that changes the tax math

Here's the part the market hasn't fully priced.

The Trump administration rescheduled state-licensed medical marijuana to Schedule III earlier this year. That change eliminates the punitive Section 280E tax treatment — the IRS rule that prevents cannabis companies from deducting ordinary business expenses, forcing them to pay tax on gross profit rather than net income. For medical-only operators like the restructured Trulieve, 280E no longer applies. The tax savings could meaningfully boost net income starting next filing period.

The bigger wild card sits on the balance sheet. Trulieve has been challenging 280E applicability retroactively to 2019, and its Q2 balance sheet carries an uncertain tax-position liability of $598.2 million. If the government grants retroactive relief, that entire amount would reverse as a one-time gain. It's not guaranteed. The DEA is still processing broader Schedule III questions, with an expedited hearing timeline that extended into mid-2026. But the asymmetry is real: the downside risk of the $598 million liability is already on the balance sheet. The upside is not yet in the price.

Florida is still the foundation

Trulieve's competitive moat isn't theoretical. In Florida — the largest U.S. medical cannabis market by revenue — Trulieve operates 170 dispensaries, representing 22% of all retail doors. In Q2, the company sold 56% more flower and 20% more oil per store than the state average. In-house brands like Modern Flower and Roll One accounted for nearly half of all units sold. Medical customer retention stands at 78%.

In Pennsylvania, Trulieve's wholesale reach extended to 85% of dispensaries. The company also opened four new Florida dispensaries during the quarter and began shipping medical products to licensed pharmacies in Georgia.

The competitive positioning hasn't cracked. The revenue decline is an optical effect of losing Harvest's top-line recognition, not a demand problem in the medical core.

The things that could break the thesis

I'm not asking investors to ignore the risks. They're real.

Debt service drag. Trulieve carries $289 million in debt at a blended rate of 9.6%. That generated $12.8 million in net interest expense in Q2 alone. At 60% gross margins and roughly 36% EBITDA margins, carrying 9.6% interest is a structural drag on profitability. Refinancing at lower rates would help materially, but the timeline is uncertain.

Stagnant SG&A. Operating expenses of $102 million are nearly flat year-over-year despite revenue declining 10%. As a percentage of revenue, SG&A rose to 37.6% from 33.5%. That's margin compression on top of the Harvest revenue loss. Operating leverage isn't working in Trulieve's favor right now.

The Harvest question. Trulieve retains 90% of Harvest economically without controlling it operationally. Harvest's future performance flows back to Trulieve through equity-method accounting. If the Harvest board makes poor decisions or the mixed-use business faces headwinds, Trulieve's earnings could take a hit without management having any say.

Near-term revenue contraction. Q3 revenue is expected around $222 million — comparable to Q2's medical-only number but roughly 18% below Q1 and Q2 combined. Full-year cash flow guidance was lowered to $225 million from $250 million. The optical revenue cliff is real, and it's why the stock has sold off.

The risk/reward setup

The market is treating a strategic restructuring as a business deterioration. Trulieve's medical core is generating roughly $224 million in annualized free cash flow with 60% gross margins and a dominant position in the largest U.S. medical market. The stock trades at 4.5x EV/EBITDA — well below the valuation you'd expect for a cash-generative business with potential tax reform upside.

The 26% year-to-date decline reflects near-term revenue visibility, not a broken business model. The Schedule III tax relief path could unlock meaningful cash flow improvements on the medical side. The $598 million retroactive tax challenge is an option that costs the market nothing to hold.

I would reassess the Buy thesis if the medical core's cash flow deteriorates materially — the Q2 operating cash flow of $53 million was below last year's $86 million, and a further slide would raise questions about the restructuring's cost. I'd also reassess if Schedule III momentum stalls or reverses, removing the primary catalyst for margin expansion.

Until those triggers fire, the valuation gap between the cash-generating medical business and the market's implied discount rate remains wide. That's not a reason to chase. It's a reason to build a position on weakness.